ConductScience.org, home

Paper42016288

High Expression of Follistatin is a Risk Factor Predicting Poor Overall Survival in Hepatocellular Carcinoma Patients.

Dai Y and 5 others. J Hepatocell Carcinoma, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. High Expression of Follistatin is a Risk Factor Predicting Poor Overall Survival in Hepatocellular Carcinoma Patients. Papers, record 42016288. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42016288

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
High Expression of Follistatin is a Risk Factor Predicting Poor Overall Survival in Hepatocellular Carcinoma Patients.
PubMed
Journal
J Hepatocell Carcinoma
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Dai YYihua
2Pan BBaoying
3Zhao JJiali
4Cai SShanglin
5Li JJianhttps://orcid.org/0000-0002-5144-2410
6Zou BBaojiahttps://orcid.org/0000-0001-8023-3434

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References35

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138572751Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2024https://conductscience.org/library/papers/38572751PubMed
215305374
High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations.
Int J Cancer2004https://conductscience.org/library/papers/15305374PubMed
339036382Cancer incidence and mortality in China, 2022.J Natl Cancer Cent2024https://conductscience.org/library/papers/39036382PubMed
430896550Clinical impact of serum α-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals.Eur J Gastroenterol Hepatol2019https://conductscience.org/library/papers/30896550PubMed
538118280Development and Validation of a Nomogram for Predicting Postoperative Early Relapse and Survival in Hepatocellular Carcinoma.J Natl Compr Canc Netw2023https://conductscience.org/library/papers/38118280PubMed
627638177Structural Biology and Evolution of the TGF-β Family.Cold Spring Harb Perspect Biol2016https://conductscience.org/library/papers/27638177PubMed
722416010Diagnostic value of serum activin A and follistatin levels in women with peritoneal, ovarian and deep infiltrating endometriosis.Hum Reprod2012https://conductscience.org/library/papers/22416010PubMed
839281724Cancer survival statistics in China 2019-2021: a multicenter, population-based study.J Natl Cancer Cent2024https://conductscience.org/library/papers/39281724PubMed
920623366Serum follistatin in patients with prostate cancer metastatic to the bone.Clin Exp Metastasis2010https://conductscience.org/library/papers/20623366PubMed
1031757999Follistatin impacts Tumor Angiogenesis and Outcome in Thymic Epithelial Tumors.Sci Rep2019https://conductscience.org/library/papers/31757999PubMed
1135142813Tumor Size, Not Small Vessel Invasion, Predicts Survival in Patients With Hepatocellular Carcinoma.Am J Clin Pathol2022https://conductscience.org/library/papers/35142813PubMed
1223456439Follistatin as potential therapeutic target in prostate cancer.Target Oncol2013https://conductscience.org/library/papers/23456439PubMed
1339817679Cancer statistics, 2025.CA Cancer J Clin2025https://conductscience.org/library/papers/39817679PubMed
1418650514Sorafenib in advanced hepatocellular carcinoma.N Engl J Med2008https://conductscience.org/library/papers/18650514PubMed
1538172802Impact of tumor size on the outcomes of hepatic resection for hepatocellular carcinoma: a retrospective study.BMC Surg2024https://conductscience.org/library/papers/38172802PubMed
1635037070Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitors.Cancer Immunol Immunother2022https://conductscience.org/library/papers/35037070PubMed
1734624411Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies.J Hepatol2022https://conductscience.org/library/papers/34624411PubMed
1833343207Hepatocellular carcinoma: epidemiology, screening, and assessment of hepatic reserve.Curr Oncol2020https://conductscience.org/library/papers/33343207PubMed
1911726573Follistatin and activin A serum concentrations in obese and non-obese patients with polycystic ovary syndrome.Hum Reprod2001https://conductscience.org/library/papers/11726573PubMed
203120188Isolation and partial characterization of follistatin: a single-chain Mr 35,000 monomeric protein that inhibits the release of follicle-stimulating hormone.Proc Natl Acad Sci U S A1987https://conductscience.org/library/papers/3120188PubMed

See all 35 referencesDownload CSV of references

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AFP174PubTator's text mininghttps://conductscience.org/library/genes/174NCBI Gene
FST10468PubTator's text mininghttps://conductscience.org/library/genes/10468NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42016288

GET https://conductscience.org/api/papers/v1/42016288/references?page=2